PMVP (PMV Pharmaceuticals, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by PMVP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | Laurie Stelzer | Director | A | — | — |
| 2026-06-05 | ARNOLD J LEVINE | Director | A | — | — |
| 2026-06-05 | KIRSTEN FLOWERS | Director | A | — | — |
| 2026-06-05 | CHARLES M BAUM | Director | A | — | — |
| 2026-06-05 | Carol Giltner Gallagher | Director | MIXED | — | — |
| 2026-03-09 | Robert Ticktin | General Counsel & COO | A | — | — |
| 2026-03-09 | David Henry Mack | President and CEO | A | — | — |
| 2026-03-09 | Deepika Jalota | Chief Development Officer | A | — | — |
| 2026-03-09 | Michael Carulli | Chief Financial Officer | A | — | — |
| 2025-10-29 | David Henry Mack | President and CEO | M | — | — |
| 2025-10-27 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell | — | — |
| 2025-09-12 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell | — | — |
| 2025-07-03 | Robert Ticktin | General Counsel & COO | Sell | — | — |
| 2025-07-03 | Deepika Jalota | Chief Development Officer | Sell | — | — |
| 2025-07-03 | Michael Carulli | Chief Financial Officer | Sell | — | — |
| 2025-07-03 | David Henry Mack | President and CEO | Sell | — | — |
| 2025-06-09 | Laurie Stelzer | Director | A | — | — |
| 2025-06-09 | CHARLES M BAUM | Director | A | — | — |
| 2025-06-09 | Richard A. Heyman | Director | A | — | — |
| 2025-06-09 | ARNOLD J LEVINE | Director | A | — | — |
| 2025-06-09 | Carol Giltner Gallagher | Director | MIXED | — | — |
| 2025-06-09 | KIRSTEN FLOWERS | Director | A | — | — |
| 2025-03-05 | Deepika Jalota | Chief Development Officer | A | — | — |
| 2025-03-05 | David Henry Mack | President and CEO | A | — | — |
| 2025-03-05 | Michael Carulli | Chief Financial Officer | A | — | — |
| 2025-01-22 | David Henry Mack | President and CEO | M | — | — |
| 2024-10-03 | Michael Carulli | Chief Financial Officer | MIXED | — | — |
| 2024-10-03 | David Henry Mack | President and CEO | MIXED | — | — |
| 2024-10-03 | Deepika Jalota | Chief Development Officer | MIXED | — | — |
| 2024-09-12 | Deepika Jalota | Chief Development Officer | Sell | — | — |
| 2024-09-12 | Michael Carulli | Chief Financial Officer | Sell | — | — |
| 2024-06-10 | CHARLES M BAUM | Director | A | — | — |
| 2024-06-10 | Richard A. Heyman | Director | A | — | — |
| 2024-06-10 | ARNOLD J LEVINE | Director | A | — | — |
| 2024-06-10 | Laurie Stelzer | Director | A | — | — |
| 2024-06-10 | KIRSTEN FLOWERS | Director | A | — | — |
| 2024-06-10 | Carol Giltner Gallagher | Director | MIXED | — | — |
| 2024-01-22 | Deepika Jalota | Chief Development Officer | A | — | — |
| 2024-01-22 | Michael Carulli | Chief Financial Officer | A | — | — |
| 2024-01-22 | David Henry Mack | President and CEO | A | — | — |
| 2023-11-24 | OrbiMed Genesis GP LLC | 10%+ Owner | Sell | — | — |
| 2023-11-13 | David Henry Mack | President and CEO | MIXED | — | — |
| 2023-09-18 | Deepika Jalota | Chief Development Officer | Sell | — | — |
| 2023-09-18 | Leila Alland | Chief Medical Officer | Sell | — | — |
| 2023-08-08 | David Henry Mack | President and CEO | M | — | — |
| 2023-06-12 | Richard A. Heyman | Director | A | — | — |
| 2023-06-12 | KIRSTEN FLOWERS | Director | A | — | — |
| 2023-06-12 | CHARLES M BAUM | Director | A | — | — |
| 2023-06-12 | Laurie Stelzer | Director | A | — | — |
| 2023-06-12 | ARNOLD J LEVINE | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,475,291 | — |
| — | Director | 6,469,911 | — |
| — | 10%+ Owner | 5,470,161 | — |
| — | Director | 4,975,291 | — |
| — | 10%+ Owner | 4,970,470 | — |
| — | 10%+ Owner | 4,474,112 | — |
| — | — | 2,528,290 | — |
| — | 10%+ Owner | 1,710,265 | — |
| — | Director | 1,101,283 | — |
| — | — | 982,708 | — |
| — | President and CEO | 904,691 | — |
| — | — | 760,267 | — |
| — | — | 751,409 | — |
| — | 10%+ Owner | 728,140 | — |
| — | Director | 409,842 | — |
| — | 10%+ Owner | 130,686 | — |
| — | Director | 114,039 | — |
| — | 10%+ Owner | 109,500 | — |
| — | General Counsel & COO | 98,695 | — |
| — | Chief Development Officer | 89,959 | — |
| — | Chief Financial Officer | 73,848 | — |
| — | Chief Medical Officer | 45,909 | — |
| — | COO, CFO | 10,600 | — |
| — | Director | 975 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PMVP quote page; the site-wide leaderboard is on the insider transactions hub.